OSI Pharma kept by Bear Stearns at outperform

OSI Pharmaceuticals Inc. was reiterated by Bear Stearns analyst Akhtar Samad at an outperform rating with a price target on the stock of $65 per share following the FDA panel vote for approval of Tarceva in pancreatic cancer as well as lung cancer. OSI Pharma shares Wednesday were down $1.02, or 3.17%, at $31.13 on volume of 4,485,875 shares versus the three-month running average of 2,191,820 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.